Volume 68, Issue 4, Pages (April 2018)

Slides:



Advertisements
Similar presentations
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir + Ribavirin in HCV GT 1,4 SOLAR-1 (Post Transplant) Phase 2 Treatment Naïve and Treatment.
Advertisements

Recent HCV treatment developments: In pursuit of perfectovir Professor Greg Dore Kirby Institute, UNSW Australia; & St Vincent’s Hospital, Sydney.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Phase 3 Treatment Experienced Source: Afdhal N, et.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir for 8 or 12 weeks in HCV GT1 ION-3 Phase 3 Treatment Naïve Kowdley K, et al. N Engl J Med.
Hepatitis web study Hepatitis web study Daclatasvir + Sofosbuvir +/- Ribavirin in Genotypes 1-3 A Trial Phase 2a Treatment Naïve and Treatment.
HCV Alert: New Data on Resistance to DAAs and Implications for Therapy
BOCEPREVIR & TELAPREVIR
Hepatitis web study Hepatitis web study Daclatasvir + Sofosbuvir +/- Ribavirin in Genotype 1-3 AI Trial Phase 2a Treatment-Naïve and Treatment-Experienced.
Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C Edward J. Gane, M.D., Catherine A. Stedman, M.B., Ch.B. New Engl J Med 2013;
R2. 임형석 / Pf. 김병호. I NTRODUCTION Chronic hepatitis C infection 130~150 million worldwide 7 genotypes genotype 1 predominates(about 70% in USA): most difficult.
Glecaprevir-Pibrentasvir (Mavyret)
Phase 3 Treatment Experienced
Sofosbuvir-Velpatasvir-Voxilaprevir in GT 3 and Cirrhosis POLARIS-3
Laboratory Diagnostics in Viral Hepatitis
HCV Treatment Options in 2017/2018: What’s Here and What’s Coming Soon
Accessing Approaches to Managing HCV Infection
Daclatasvir + Sofosbuvir +/- Ribavirin in Genotype 1-3 Trial
Genotype 1 HCV in 2016: Clinical Decision Making in a Time of Plenty
Phase 3 Treatment Experienced
Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir in GT1b TURQUOISE-III
Glecaprevir-Pibrentasvir in Non-Cirrhotic Genotype 2 ENDURANCE-2
2017: HIV, STD, HBV, and HCV Update
Sofosbuvir and Ledipasvir Combination with and without Ribavirin in Patients with Hepatitis C Virus Infection; Preliminary Report of an Experience from.
Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the ‘accordion’ regimen?  Patrick Marcellin, E. Jenny Heathcote,
Resistance to HCV direct-acting antivirals: What should we know?
Diagnosis and Point of Care Testing of Hepatitis C
Guangdi Li, Erik De Clercq
Hepatitis Tutoring Part 2
SOF/VEL/VOX and Other Sofosbuvir-Based Direct-Acting Antiviral Therapies for Hepatitis C Virus in Patients Receiving Opioid Substitution Therapy: An Analysis.
Newly Approved Hepatitis C Virus Drugs: Approach to Initial Therapy
Direct-Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection Are Cost-Saving  Jagpreet Chhatwal, Tianhua He, Chin Hur, Maria.
DAA’s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?
Volume 65, Issue 5, Pages (November 2016)
SUSTAINED VIROLOGICAL RESPONSE IN HCV PATIENTS TREATED WITH DACLATASVIR+SOFOSBUVIR, WITH OR WITHOUT RIBAVIRIN: A LARGE FIELD-PRACTICE EXPERIENCE Rodolfo.
Resistance to Direct Acting Antiviral Therapy
Phase 2 Treatment Naïve (unfavorable baseline treatment characteristics) Ledipasvir-Sofosbuvir +/- 3rd DAA in HCV Genotype 1 NIAID SYNERGY: Genotype.
Case 53-year-old Black Man
Figure 1 Patients cured of HCV infection
Volume 69, Issue 2, Pages (August 2018)
NS5A inhibitors in the treatment of hepatitis C
CHIA SẺ KINH NGHIỆM ĐIỀU TRỊ VIÊM GAN SIÊU VI C
中國醫藥大學附設醫院 消化系肝膽內科 賴學洲醫師
Identification of the Best Direct-Acting Antiviral Regimen for Patients With Hepatitis C Virus Genotype 3 Infection: A Systematic Review and Network Meta-analysis 
New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges
Unraveling the genetic predisposition of ribavirin-induced anaemia
Cost-Effectiveness Analysis of New HCV Treatments in Egyptian Cirrhotic and Non- Cirrhotic Patients: A Societal Perspective  Gihan Hamdy Elsisi, MSc, PhD,
Volume 146, Issue 3, Pages e1 (March 2014)
Ype P. de Jong, Charles M. Rice, Alexander Ploss  Journal of Hepatology 
Volume 59, Issue 4, Pages (October 2013)
Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2
Phase 2 Treatment Naïve and Treatment Experienced
Ledipasvir-Sofosbuvir +/- Ribavirin for 8 or 12 weeks in HCV GT1 ION-3
Jordan J. Feld, Graham R. Foster  Journal of Hepatology 
Marc van der Valk, Hans L. Zaaijer, Arnon P. Kater, Janke Schinkel 
From non-A, non-B hepatitis to hepatitis C virus cure
Darius Moradpour, Arash Grakoui, Michael P. Manns 
New HCV therapies on the horizon
No HBV or HIV co-infection
Phase 2 Treatment Naïve Elbasvir-Grazoprevir + Sofosbuvir in Treatment-Naïve HCV Genotype 1 or 3 C-SWIFT Poordad F, et al. EASL 2015; Abstract O006.
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Volume 61, Issue 1, Pages S45-S57 (November 2014)
Martina Gambato, Sabela Lens, Miquel Navasa, Xavier Forns 
What Does the Future Hold and What Will It Mean for Patients?
HCV epidemiology in high-risk groups and the risk of reinfection
Alessio Aghemo, Maria Francesca Donato  Gastroenterology 
Phase 3 Treatment-Naïve and Treatment-Experienced
Phase 3 Treatment-Naïve and Treatment-Experienced
Johannes Vermehren, James S. Park, Ira M. Jacobson, Stefan Zeuzem 
Glecaprevir-Pibrentasvir in Non-Cirrhotic Genotype 2 ENDURANCE-2
Reversion of disease manifestations after HCV eradication
Presentation transcript:

Volume 68, Issue 4, Pages 814-826 (April 2018) Eliminating hepatitis C within low-income countries – The need to cure genotypes 4, 5, 6  Tarik Asselah, Tarek Hassanein, Imam Waked, Abdellah Mansouri, Geoffrey Dusheiko, Edward Gane  Journal of Hepatology  Volume 68, Issue 4, Pages 814-826 (April 2018) DOI: 10.1016/j.jhep.2017.11.037 Copyright © 2017 Terms and Conditions

Fig. 1 HCV GT4, GT5, and GT6 distribution worldwide. HCV GT4, GT5, and GT6 infect an estimated 30 million people worldwide and account for approximately 20% of global HCV infections. Journal of Hepatology 2018 68, 814-826DOI: (10.1016/j.jhep.2017.11.037) Copyright © 2017 Terms and Conditions

Fig. 2 Mode of action of direct-acting antivirals (DAAs) and developmental milestones of approved DAAs. (A) DAA with different viral targets (NS3 protease inhibitors, nucleoside/nucleotide analogues and non-nucleoside inhibitors of the RNA-dependent RNA polymerase and NS5A inhibitors) have been developed in combination and leads to high efficacy, reduced risk of resistance and shorten treatment duration. (B) Development milestones of approved DAAs. DAA, direct-acting antiviral; DCV, daclatasvir; DSV, dasabuvir; EBV, elbasvir; GLE, glecaprevir; GRZ, grazoprevir; GT, genotype; LDV, ledipasvir; NS, non-structural protein; OMV, ombitasvir; PIB, pibrentasvir; PTV, paritaprevir; RBV, ribavirin; RTV, ritonavir; SMV, simeprevir; SOF, sofosbuvir; VEL, velpatasvir; VOX, voxilaprevir. Journal of Hepatology 2018 68, 814-826DOI: (10.1016/j.jhep.2017.11.037) Copyright © 2017 Terms and Conditions

Fig. 3 Treatment with DAAs results in high rates of cure in people who inject drugs.85–88 DAA, direct-acting antiviral; DSV, dasabuvir; EBV, elbasvir; GRZ, grazoprevir; LDV, ledipasvir; OMV, ombitasvir; PTV, paritaprevir; RBV, ribavirin; RTV, ritonavir; SOF, sofosbuvir; SVR12, sustained virological response at week 12; VEL, velpatasvir. Journal of Hepatology 2018 68, 814-826DOI: (10.1016/j.jhep.2017.11.037) Copyright © 2017 Terms and Conditions